Streetbeat News

Earnings

DNMR

Danimer Scientific (NYSE:DNMR) is scheduled to release its quarterly earnings report on March 28, 2024, with an estimated EPS of $-0.38. Analysts and investors are keen on whether DNMR will surpass this estimate and provide positive future guidance. The company's past earnings performance shows a pattern of not meeting EPS estimates, leading to significant stock price fluctuations. Currently, DNMR shares are trading at $1.03, marking a 65.91% decrease over the last year, indicating investor concern ahead of the earnings announcement.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 3:00 pm

ABT

Abbott Laboratories (ABT) is analyzed in comparison with its competitors in the Health Care Equipment & Supplies industry. Key financial metrics indicate ABT is undervalued with lower PE, PB, and PS ratios than the industry average. Despite lower ROE suggesting less efficiency in profit generation, ABT shows strong operational performance with high EBITDA and gross profit. However, its revenue growth is significantly lower than the industry average, indicating slower expansion.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 3:00 pm

TPR

Analyst evaluations of Tapestry (NYSE:TPR) over the last three months show diverse outlooks, with a recent trend towards bullish sentiment. The average 12-month price target for TPR is now $50.6, reflecting a 15.0% increase from the previous target. Tapestry's financial performance is strong, with notable revenue growth, net margin, ROE, and ROA, despite a high debt-to-equity ratio. The company's acquisition of Capri, including brands like Michael Kors, Versace, and Jimmy Choo, could further impact its market position.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 3:00 pm

OUST

Ouster's stock price increased following the announcement of its Q4 financial results and future guidance.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 2:59 pm

GREE

Greenidge Generation Holdings Inc (NASDAQ:GREE) is trading flat at $3.25 ahead of its Q4 earnings report. Analysts expect an EPS of 20 cents on revenue of $26.7 million. The company faces challenges from high operational costs and intense competition in the Bitcoin mining industry, which may affect its profitability despite higher Bitcoin prices. GREE's 52-week trading range is between $1.55 and $9.26.

Portfolio Pulse from Henry Khederian

March 27, 2024 | 2:56 pm

CCL

CUK

Carnival Corp reported a 22% year-on-year increase in Q1 FY24 sales to $5.406 billion, slightly below analyst expectations. Passenger Cruise Day and occupancy rates increased, with total customer deposits hitting a record $7.0 billion. The company saw a significant improvement in operating income and margins, with an adjusted EPS loss smaller than expected. Carnival's outlook for FY24 includes higher adjusted EBITDA and net yields, with capital expenditures projected at $2.3 billion. Despite positive performance indicators, CCL shares dropped 1.97% due to the report slightly missing sales estimates and potential impacts from an event in Baltimore.

Portfolio Pulse from Shivani Kumaresan

March 27, 2024 | 2:51 pm

NVCR

Novocure Ltd (NASDAQ:NVCR) announced positive results from the Phase 3 METIS clinical trial for its Tumor Treating Fields (TTFields) therapy in treating brain metastases from non-small cell lung cancer. The study met its primary endpoint, showing a significant improvement in time to intracranial progression compared to supportive care alone. TTFields therapy was well-tolerated, with a median time to intracranial progression of 21.9 months versus 11.3 months for supportive care alone. Preliminary analysis of secondary endpoints showed positive trends but did not reach statistical significance. Novocure's Premarket Approval application for TTFields therapy in non-small cell lung cancer has been accepted by the FDA. Following the news, NVCR shares surged by 10.70% to $14.49.

Portfolio Pulse from Vandana Singh

March 27, 2024 | 2:17 pm

GE

Benzinga's options scanner detected significant trading activity in General Electric (NYSE:GE) options, with over 13 trades amounting to $975,239. The trades indicate a bullish sentiment, aiming for a price target between $167.5 and $170. GE's current market price is $175.48, with a volume of 881,788, suggesting it may be overbought. The company is set to release earnings in 27 days, and its performance is closely watched by investors.

Portfolio Pulse from Benzinga Insights

March 27, 2024 | 2:16 pm

CTAS

MRK

NOAH

PAYS

Cintas Corporation reported better-than-expected Q3 financial results, leading to a 9.7% rise in its shares. Other companies like PaySign, Noah Holdings, and NuScale Power also saw significant gains after positive financial reports or upgrades. Notably, Merck received FDA approval for a new treatment, contributing to a 4.4% increase in its stock price.

Portfolio Pulse from Avi Kapoor

March 27, 2024 | 2:03 pm

IDAI

Trust Stamp reported a FY23 EPS of $(1.07), improving from $(2.55) YoY, with revenue decreasing to $4.56M from $5.39M. The reduction in revenue was attributed to the end of the ICE pilot and a shift towards SaaS sales, offset by a significant reduction in SG&A expenses. The company also reduced its operating loss to $7.64M from $12.08M YoY and strengthened its balance sheet through equity investments, raising a total of $10.32M. Trust Stamp continues to invest in R&D, boasting a portfolio of 20 issued patents and 15 pending, focusing on AI technology.

Portfolio Pulse from Benzinga Newsdesk

March 27, 2024 | 2:02 pm